Derivatives of sobetirome
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
1. A compound with the structure:
or any pharmaceutically acceptable salt thereof, where R1 is an alkylamino.
2. The compound of claim 1 where R1 is substituted alkylamine, cycloalkylamino, or substituted cycloalkylamino.
3. The compound of claim 1 wherein R1 is ethylamino, ethyl(N,N,N)-trimethylamino, ethylmorpholinyl, ethyl(N,N)-dimethylamino, 3-(N-methyl)azetidinyl, 4-pyrrolidinyl, 3-pyrrolidinyl, 2,2-dimethylethylamino, 3-(3-trifluoromethyl)azetidinyl, 2-pyrrolidinyl, 2-methylethylamino, 2-trifluoromethylamino, N-methyl-ethylomino, 1-methyl-(N,N)dimethylethylamino, 1-methyl-2-imazodinylethylamino; 1-methyl-2-keto-ethylamino, 1-isopropyl-ethylamino, and 1-isopropyi-N-methyl-ethylamino.
4. The compound of claim 3 wherein R1 is 2-methylethylamino further comprising R and S enantiomers.
5. The compound of claim 3 with the structure:
6. The compound of claim 5 wherein the compound is a halide salt.
7. The compound of claim 3 with the structure selected from:
8. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.